ARTICLE SUMMARY:
Device industry officials who are engaged in Brazil affairs praise the country’s regulatory agency, ANVISA, for employing a rigorous rule-making process to develop a policy for monitoring orthopedic implant prices to help counter corruption, while steering clear of pursuing direct price controls.
Device industry advocates say they are pleased with Brazil’s new plans for an implant price-monitoring initiative, both for what it is, and what it is not.
